DPP-4 Inhibitor·Endocrinology - Oral Antidiabetics

Linagliptin

Type 2 Diabetes Mellitus

Authority requiredPBSORALTrajenta, Trajentamet (combo with metformin)5 mg tablet+2

No source link confirmed for this record yet. Its own source notes are under Additional.

At a glance

Max Dose

5 mg/day

Half-life

12 h

Renal Adj.

NOT REQ.

Caution: Pancreatitis

RARE

Cautions

Avoid / Cautions

History of pancreatitis. Type 1 Diabetes. Pregnancy Category B3.

Where it stands

Rapid Summary

Overview

DPP-4 Inhibitor (Gliptin). Blocks the breakdown of endogenous GLP-1. Unique among gliptins because it requires absolutely ZERO dose adjustment in renal failure.

Clinical Focus

The absolute safest and most convenient oral antidiabetic for a patient with severe, fluctuating, or end-stage chronic kidney disease.

Bottom Line

Linagliptin is the only DPP-4 inhibitor requiring no renal dose adjustment (hepatic elimination), but provides modest HbA1c reduction and lacks cardiovascular outcome benefits.

Formulation & Access

Brand Names

Trajenta, Trajentamet (combo with metformin)

Oral Routes

Tablets (5 mg).

Prescribing & PBS

Authority Required (PBS).

Indications & Use

Primary

PBSTGA

Type 2 Diabetes Mellitus.

Clinical Place

The go-to add-on agent when Metformin fails or is contraindicated, specifically in patients with an eGFR < 30 where Sitagliptin would require complex dose reductions.

Quick reference

Class & Role

DPP-4 Inhibitor — DPP-4 Inhibitor (Gliptin).

Route / Formulation

Tablets (5 mg). (Trajenta, Trajentamet (combo with metformin))

Usual Dose & Max

PO 5 mg OD (with or without food). Max 5 mg/day (Flat dosing).

Key Indication Doses

Type 2 Diabetes: PO 5 mg OD (with or without food). Renal / Hepatic Impairment: No dose adjustments required for any degree of renal or hepatic impairment.

Best Uses

Linagliptin is the only DPP-4 inhibitor requiring no renal dose adjustment (hepatic elimination), but provides modest HbA1c reduction and lacks cardiovascular outcome benefits.

Key Risks

Gastrointestinal: Acute pancreatitis (rare but severe). LOW — Nausea, diarrhea. Musculoskeletal: Severe, disabling arthralgia (joint pain) has been linked to the entire DPP-4 class. Resolves on cessation. Endocrine: Zero hypoglycemia risk when used as monotherapy. Weight neutral.

Key Interactions

Strong CYP3A4/P-gp inducers (Rifampicin) significantly drop linagliptin blood levels, reducing efficacy.

Monitoring

Warn patient to report severe, radiating upper abdominal pain immediately (pancreatitis). Routine HbA1c.

Clinical Pearl

Every other oral diabetes drug (Metformin, Gliclazide, Sitagliptin, Empagliflozin) either stops working or becomes highly toxic in severe renal failure. Linagliptin is the only oral drug you can safely give at full dose to a dialysis patient.

Access

Authority requiredTrajenta, Trajentamet (combo with metformin)5 mg tablet

Brand: Trajenta, Trajentamet (combo with metformin)
PBS status: Authority required
Formulation: Tablets (5 mg).

From this page

No calculator, monitoring schedule or factsheet is linked to this medicine page yet.

DPP-4 Inhibitor·Endocrinology - Oral Antidiabetics

Linagliptin

Type 2 Diabetes Mellitus

Authority requiredPBSORALTrajenta, Trajentamet (combo with metformin)5 mg tablet+2

No source link confirmed for this record yet. Its own source notes are under Additional.

At a glance

Max Dose

5 mg/day

Half-life

12 h

Renal Adj.

NOT REQ.

Caution: Pancreatitis

RARE

Cautions

Avoid / Cautions

History of pancreatitis. Type 1 Diabetes. Pregnancy Category B3.

Where it stands

Rapid Summary

Overview

DPP-4 Inhibitor (Gliptin). Blocks the breakdown of endogenous GLP-1. Unique among gliptins because it requires absolutely ZERO dose adjustment in renal failure.

Clinical Focus

The absolute safest and most convenient oral antidiabetic for a patient with severe, fluctuating, or end-stage chronic kidney disease.

Bottom Line

Linagliptin is the only DPP-4 inhibitor requiring no renal dose adjustment (hepatic elimination), but provides modest HbA1c reduction and lacks cardiovascular outcome benefits.

Formulation & Access

Brand Names

Trajenta, Trajentamet (combo with metformin)

Oral Routes

Tablets (5 mg).

Prescribing & PBS

Authority Required (PBS).

Indications & Use

Primary

PBSTGA

Type 2 Diabetes Mellitus.

Clinical Place

The go-to add-on agent when Metformin fails or is contraindicated, specifically in patients with an eGFR < 30 where Sitagliptin would require complex dose reductions.

Quick reference

Class & Role

DPP-4 Inhibitor — DPP-4 Inhibitor (Gliptin).

Route / Formulation

Tablets (5 mg). (Trajenta, Trajentamet (combo with metformin))

Usual Dose & Max

PO 5 mg OD (with or without food). Max 5 mg/day (Flat dosing).

Key Indication Doses

Type 2 Diabetes: PO 5 mg OD (with or without food). Renal / Hepatic Impairment: No dose adjustments required for any degree of renal or hepatic impairment.

Best Uses

Linagliptin is the only DPP-4 inhibitor requiring no renal dose adjustment (hepatic elimination), but provides modest HbA1c reduction and lacks cardiovascular outcome benefits.

Key Risks

Key Interactions

Strong CYP3A4/P-gp inducers (Rifampicin) significantly drop linagliptin blood levels, reducing efficacy.

Monitoring

Warn patient to report severe, radiating upper abdominal pain immediately (pancreatitis). Routine HbA1c.

Clinical Pearl

Access

Authority requiredTrajenta, Trajentamet (combo with metformin)5 mg tablet

Brand: Trajenta, Trajentamet (combo with metformin)
PBS status: Authority required
Formulation: Tablets (5 mg).

From this page

No calculator, monitoring schedule or factsheet is linked to this medicine page yet.